HONG KONG, Dec. 13, 2010 /PRNewswire-Asia-FirstCall/ -
China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"),
the first and largest cord blood banking operator in China, today announced the completion of its
previously announced warrant exchange offer, which allowed warrant
holders to receive one ordinary share for every eight warrants
outstanding. The Company issued 1,627,518 ordinary shares,
equivalent to 2.2% of shares outstanding as of December 10, 2010, in exchange for 13,020,236
warrants. Investors participating in the warrant exchange
offer are subject to a 45-day lock up period with regard to
ordinary shares acquired in the exchange offer.
Ms. Ting Zheng, Chairperson and CEO of China Cord Blood
Corporation commented, "We believe shareholders will appreciate our
simplified capital structure. With no further dilution,
shareholders will fully enjoy the benefits of our operational
accomplishments and robust growth, even on a per share basis.
With all the stakeholders' interests now fully aligned, we
will continue to expand our dominance within the China market, as well as the Asia Pacific region, to better capitalize on
emerging opportunities."
Immediately after giving effect to the warrant exchange, China
Cord Blood Corporation will have 75,406,868 ordinary shares issued
and outstanding, and any remaining warrants outstanding that are
not exercised will expire at 5:00
p.m. U.S. Eastern Time on the date of this press
release.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood
banking operator in China in terms
of geographical coverage and is the only cord blood banking
operator with multiple licenses. Under the current PRC
government regulations, only one licensed cord blood banking
operator is permitted to operate in each licensed region and only
seven licenses have been authorized as of today. China Cord
Blood Corporation provides cord blood collection, laboratory
testing, hematopoietic stem cell processing, and stem cell storage
services. For more information, please visit our website at
http://www.chinacordbloodcorp.com.
Important Additional Information
This press release and the description contained herein are for
informational purposes only and are not an offer to purchase or a
solicitation of an offer to sell securities of the Company.
For more information, please contact:
China Cord Blood Corporation
|
|
Ms. Joeling Law
|
|
Tel: (+852) 3605-8180
|
|
Email: ir@chinacordbloodcorp.com
|
|
|
|
ICR, LLC
|
|
In New York: Ashley M. Ammon:
1-646-277-1227
|
|
In Beijing: Wen Lei Zheng:
+86-10-6583-7510
|
|
|
SOURCE China Cord Blood Corporation